Information  X 
Enter a valid email address

Uniphar PLC (UPR)

  Print      Mail a friend

Friday 16 August, 2019

Uniphar PLC

Exercise of Over-allotment Option

RNS Number : 2544J
Uniphar PLC
16 August 2019
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

This announcement does not constitute, or form part of, and should not be construed as, an offer for sale or subscription or solicitation of or invitation to make any offer to buy or subscribe for any securities. Neither this announcement nor any part of it shall form the basis of or be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever. A copy of the Admission Document published by the Company is available for inspection on the Company's website at www.uniphar.ie subject to certain access restrictions.

 

 

16 August 2019

 

UNIPHAR PLC

 

Exercise of Over-Allotment Option

 

 

Uniphar plc (the "Company") today announces that, in connection with its Placing and Admission (the "Offering"), J&E Davy, as stabilisation manager, has given notice to exercise the over-allotment option granted by Uniphar plc in respect of 3,818,004 Ordinary Shares in the Company (the "Over-allotment Shares") amounting to €4.39 million of further gross proceeds payable to the Company resulting in total gross proceeds of €139 million from the Placing.

 

Application has been made for 3,818,004 Ordinary Shares to be admitted to trading on Euronext Growth, a market operated by Euronext Dublin and AIM, a market operated by the London Stock Exchange. It is expected that such admission will occur at 8.00 a.m. (Dublin time) on 21 August 2019.

 

Following the exercise of the Over-allotment Option and issue of the 3,818,004 Over-allotment Shares, the total issued share capital of the Company will be 273,015,254 Ordinary Shares.

 

 

--- ENDS ---

 

For further details contact:

 

Uniphar                                                                                   

 

Brian O'Shaughnessy

Director of Investor Relations and Corporate Development

 

+353 (0) 1 428 7777

 

 

[email protected]

 

 

Davy

(Joint Broker, Nominated Adviser and Euronext

Growth Adviser)          

 

Fergal Meegan

Barry Murphy

Tom Tynan

 

 

+353 (0) 1 679 6363

RBC Capital Markets (Joint Broker)                                                                  

Darrell Uden

Jonathan Hardy

Thomas Debrosse

 

 

+44 (0) 20 7653 4000

Q4 PR

(Public Relations Adviser to Uniphar)                                      

 

Iarla Mongey

 

 

+353 (0) 1 475 1444

or

+353 87 235 6461

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access, and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK, the Benelux and the US.

 

In Commercial & Clinical, the Group provides sales, marketing and distribution solutions to pharmaceutical and medical devices manufacturers on an outsourced basis.

 

In Product Access, the Group is growing two distinct service offerings: 1) sourcing and supplying unlicensed medicines to meet the needs of pharmacy customers (On-Demand Access); and 2) managing the release of speciality medicines for pharmaceutical manufacturers to specifically approved patient populations (Exclusive Access).

 

Supply Chain & Retail is an Irish only business for the Group, with Uniphar being an established market leader in Ireland with c.50% of the wholesale market servicing retail pharmacy, supported by a network of 235 owned and franchised pharmacies.

 

 

IMPORTANT NOTICES

 

 

This announcement is for information purposes only and does not constitute, or form part of, and should not be construed as, an offer for sale or subscription or solicitation of or invitation to make any offer to buy or subscribe for any securities. Neither this announcement nor any part of it shall form the basis of or be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever. The information in this announcement is for regulatory purposes.

 

This announcement is an advertisement and not a prospectus or admission document, and investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the Admission Document published by the Company in connection with the Offering. The Admission Document is available on the Company's website, www.uniphar.ie, subject to certain access restrictions. 

 

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.  This announcement is not an offer of securities for sale into the United States.  The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration.  No public offering of securities is being made in the United States.

 

The distribution or publication of this announcement may be restricted by law in certain jurisdictions, and persons who gain possession of this announcement are required to inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. No action has been taken to permit possession or distribution or publication of this announcement, other than in Ireland and the United Kingdom.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLLFSTTIIELIA

a d v e r t i s e m e n t